Identity
- Security key
- 16170
- Ticker
- GOVX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 1995-02-01
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- GOVX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $3,780,713.4
- Shares outstanding (class)
- 7,369,243
- Shares outstanding (weighted)
- 5,210,465
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 19
- Location
- SMYRNA, GA
- Homepage
- https://www.geovax.com
- Description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Market cap and share counts drift.